Latest

The day's market news, with the argument attached

New notes every trading day on earnings, policy and market structure. Each one opens with the conclusion, then the evidence, then the companies it hits.

What Big Funds Own22 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-08-04

Bessent’s yen request turned the Fed’s FX backstop into a global market-shock switch—starting with $60B per week insight cover

Markets / Event

Aug 4, 2026

7 min read

Bessent’s yen request turned the Fed’s FX backstop into a global market-shock switch—starting with $60B per week

When Scott Bessent urged the Fed to “upsiz[e]” its FIMA Repo Facility, the US stopped treating yen defense as just a Treasury operation. That matters because the Fed backstop (up to $60B in USD lending for up to seven days) can amplify cross-border funding stress and make “155 per dollar” a global volatility trigger rather than a Japan-only headline.

FIMA USD lending cap: $60BFIMA loan duration: Up to 7 days

Broadridge’s “Profit Gain” Isn’t the Event Cycle—It’s Recurring Market Plumbing Getting More Utilized

Broadridge’s latest earnings show profit rising faster than event-driven activity, with recurring revenue growth lifting both segment earnings and adjusted EPS. The key tell: governance/communications (ICS) keeps scaling, and new proxy/disclosure coverage for tokenized securities suggests the “shareholder communications toll booth” is widening rather than just riding transaction spikes.

Recurring revenue growth (Q3 FY26): 7%Recurring revenues (9 months): $3,336M

Caterpillar's Raised 2026 Outlook Is the First Real “AI-to-Earthmoving” Stress Test

Caterpillar lifted its 2026 growth forecast after reporting results that linked demand to AI data-center buildouts—specifically power-generation and backup power needs tied to new sites. If that forecast holds, the next margin pool won’t stay in the server rack; it will show up as earthmoving, power infrastructure, and rental/field-capacity decisions.

TTM revenue: $70.755BTTM net income: $9.419B

Chipotle [CMG] Isn’t the Suspected Outbreak—But the “Traffic Shock” Math Still Applies

A primary FDA update on a 2026 multistate foodborne illness outbreak implicated Taco Bell locations and iceberg lettuce from Taylor Farms de Mexico—not Chipotle. Even so, Chipotle [CMG] still faces the same investor problem: how fast a suspected outbreak narrative can pull transactions down when the model is already sensitive to traffic and menu disruption.

Chipotle revenue (FY2023): $9.87BChipotle revenue (FY2024): $11.31B

Clorox Just Got a Real-Staples “Re-Rate” Test—Purell Is Doing the Work

Clorox’s GOJO/Purell bolt-on did not just add scale—it changed the company’s 2026 outlook math, with guidance explicitly tracking margin headwinds and transaction costs tied to the deal. For investors, the question shifts from “does hygiene sell volumes?” to “can margin-mix from higher-quality hygiene assets defend earnings through the AI-era spend normalization?”

Fiscal 2026 net sales outlook (updated): down ~6%Fiscal 2026 gross margin outlook (updated): down ~250–300 bps

Electronic Arts‘ $55B PIF Take-Private Just Met a Bookings Miss—So the Console Live-Services Pipeline Is the Only Deal Math That Matters

EA’s Saudi-PIF-backed $55B go-private deal is set to close around Aug. 4, 2026, but the timing is now being judged against a Q1 bookings miss. The market’s “deal” framing is secondary: investors should focus on whether EA can sustain console/PC live-service monetization through its multi-year content cadence to make the cash ramp required by an LBO credible.

Take-private value: $55BPer-share price: $210

Gilead Sciences's HIV growth buys time—but only if its R&D spend translates into “next-legs” before Biktarvy peak cash turns into renewal risk

Gilead Sciences reported base business up 8% and raised full-year guidance to expect HIV sales growth of 8% in 2026. But the investable question is how long that HIV duration can keep funding pipeline bets: in FY2025, free cash flow was $9.46B while R&D is ~$5.80B—meaning the “duration” thesis hinges on near-term clinical conversions, not just franchise resilience.

1Q 2026 base business growth: 8% YoY1Q 2026 HIV product sales: $5.0B

Iron Ore at a 13-Month Low Turns Beijing’s Stimulus Into a Math Problem at ~$95, Not ~$115

A slide in iron ore forces investors to separate “China steel demand” from “headline price.” Using China’s iron-ore import/inventory signals, the real test for the whole bulk-materials chain is whether stimulus can lift steel throughput enough for benchmarks to stay above the economic clear price—otherwise high-cost supply is still punished while US/EU steel margins get a temporary cushion.

China iron ore imports (1H2026): 628.87M tonsChina iron ore imports (June 2026): 112.69M tons

Eli Lilly's “Early-Access” Move Is a TAM Pre-Pricing Mechanism

Lilly’s “early access” to its next-gen obesity drug (retatrutide) is not charity—it is a controlled go-to-market rehearsal that can pre-price demand and steer where patients (and cash-pay channels) land once the broader launch hits. In this model, the value comes from learning-and-pricing ahead of approval, while the financials show Lilly can fund growth and scale investment despite periods of low free cash flow.

Weight loss at 80 weeks (12 mg vs placebo): -28.3% vs -2.2%≥30% weight loss (12 mg): 45.3%

McDonald’s U.S. Value Push Didn’t Fail—But It May Be Losing Its “Traffic Engine” as Growth Shifts Toward Check

McDonald’s latest U.S. comparable sales growth has remained positive (3.9% in Q1 2026), but the company’s own disclosure framework—where comp sales can rise via average check even as guest traffic slows—makes “value” harder to underwrite purely as traffic recovery. For investors, the key question is whether value meals are still expanding guest counts, or increasingly only remixing purchases in ways that protect revenue while compressing franchise economics.

McDonald’s U.S. comparable sales: ↑ 3.9%

Merck's “Quarter Beat” Is a Patent-Reset Reality Check

Merck’s latest reported strength shows how much the Keytruda franchise can still carry, but it doesn’t answer the real question: whether Merck has built a durable replacement economics model before biosimilar pressure starts in December 2028. The company also guided FY2026 sales upward into a window that still precedes the hardest 2028–2029 exclusivity step-down.

Keytruda/Keytruda QLEx (1Q 2026): $8.0BFY2026 sales outlook (range): $65.8B–$67.0B

Read article

AI diplomacy is repricing US chips: China’s Mythos anxiety turns the next frontier-model release into a Trump–Xi bargaining input insight cover

Industry News

Aug 4, 2026

NVDA · AVGO•9 min read

AI diplomacy is repricing US chips: China’s Mythos anxiety turns the next frontier-model release into a Trump–Xi bargaining input

U.S. policy is building a voluntary, federally benchmarked “covered frontier model” review process for advanced AI with cyber risk, ahead of a Trump–Xi summit sequence. If China is truly focusing on Anthropic’s Mythos-class cyber capabilities as an “offensive weapon” concern, then the next frontier-model decision window is effectively being priced into the same trade corridor that governs advanced AI chip access—making NVIDIA, Broadcom, AMD, and Micron sensitive to diplomacy headlines.

Cyber-capability benchmarking: ClassifiedDeveloper access window: Up to 30 days

onsemi's guided-up AI data-center demand is shifting the “power bottleneck” from GPUs to SiC and power-silicon

In its latest quarter and outlook, onsemi guided to faster AI data-center momentum, with silicon-carbide and power-silicon demand framed as scaling alongside broader power architectures. The practical investor read: when hyperscalers add AI racks, the spend doesn’t only show up in GPUs/HBM—it increasingly pulls forward discrete power devices, SiC, and server-power capacity, tightening the link between AI capex and onsemi’s growth.

Q2 2026 revenue (reported): $1.604BAI data-center revenue outlook: more than doubles

Amazon’s “transaction-entry” defense just got court-tested—AI shopping agents may need a new payments-and-permissions layer

A U.S. judge granted Amazon a preliminary injunction blocking Perplexity’s Comet “agentic” shopping tool from accessing protected parts of Amazon on behalf of users. The ruling reframes AI-agent commerce as a permissions-and-integration problem (not just a scraping or UX problem), which changes who profits: the interface owner, the identity/payment rail, or the discovery layer.

Injunction posture: PreliminaryJudge: M. Chesney

Pfizer's $2.5B save is the easy part; the question is what it funds after the patent cliff

Pfizer has repeatedly expanded its “cost realignment” targets, with the program originally including at least $2.5B of additional net savings expected to be realized in 2024 and later culminating in ~$5.7B through 2026. The hard investor question is whether these savings are protecting (or crowding out) the cash needed for the post-patent-cliff commercial and pipeline reset.

Operating cash flow (FY2025): $11.7BFree cash flow (FY2025): $9.1B

Procter & Gamble's $3.8B Thorne bet shifts “wellness” from shelf risk to premium supply-chain leverage

Procter & Gamble is reportedly paying $3.8B in cash to acquire Thorne, a science-driven supplements brand, with closing expected later in 2026. The investor question is not “does supplements grow?”—it’s whether P&G can add a higher-growth, higher-trust revenue stream without sacrificing the margin discipline that supports its staple-like cash generation.

FY2026 revenue: $87.0BFY2026 net income: $18M

Prudential Financial's PGIM beat is real—but the deeper signal is whether the business is shifting toward less capital-heavy earnings

In Q1 2026, Prudential Financial reported PGIM adjusted operating income of $190m (+22% YoY), while its insurance-side profitability weakened in the same quarter. The implication for investors: if fee-based growth keeps pacing (and insurance capital intensity keeps easing), PRU may deserve a valuation framework closer to asset managers than traditional insurers.

PGIM adjusted operating income (Q1 2026): $190mInsurance (Group Insurance) adjusted operating i: $38m

TikTok’s three pre-trial teen settlements just pushed Meta/Snap/Alphabet into the “Section 230 reserve mark-up” era

TikTok agreed to settle a landmark teen social-media addiction case just before the trial began, after Snap also settled and while Meta and YouTube (Alphabet) faced the bellwether. The result is less about payout size and more about litigation pricing: once one “architected-for-addiction” case resolves early, it increases the probability-weighted loss exposure and forces platforms to carry higher legal reserves—re-anchoring the ad-market’s Section 230 liability discount.

Bellwether damages (Meta/Google portion): $6.0MSettlement terms disclosed?: No

Toyota’s weak-yen “profit” story is increasingly a China-write-off + FX-translation trade, not a demand rebound

Toyota is guiding higher operating profit even as it warns China weakness is persisting, turning the weak-yen tailwind into an accounting translation effect rather than a volume recovery. For investors, that means the next catalyst is less about Japanese pricing power and more about whether FX tailwinds survive and whether China demand stabilizes.

Event Date: 2026-08-04Topic Type: Earnings

America’s trade deficit shrank because imports fell—watch the supply-chain “pause” behind the headline

In June, the U.S. goods trade deficit narrowed to $101.5B largely because imports of goods fell $8.2B m/m. That looks GDP-friendly on the surface, but it can also signal a demand pause and inventory/freight timing effects—typically showing up first in logistics and in companies with high import exposure.

International trade deficit (goods): $101.5BMonth-over-month change in deficit: -$4.4B

Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer